Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FENC NASDAQ:HRTX NASDAQ:IBIO NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$7.09-0.2%$6.92$5.65▼$9.92$245.23M0.91153,487 shs2,463 shsHRTXHeron Therapeutics$0.95-0.2%$0.97$0.74▼$2.30$179.77M1.71.95 million shs876,699 shsIBIOiBio$1.64-1.5%$2.10$0.56▼$3.82$59.09M1.231.49 million shs131,934 shsVYGRVoyager Therapeutics$4.17+1.1%$4.03$2.64▼$5.55$251.05M1.26649,863 shs129,876 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies+2.45%+8.56%+22.20%-8.86%+18.93%HRTXHeron Therapeutics-21.05%-24.78%+11.99%-24.78%-54.73%IBIOiBio-2.92%+4.40%-23.15%-26.87%+165,999,900.00%VYGRVoyager Therapeutics+1.73%+9.57%+10.16%+11.35%+27.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFENCAdherex Technologies$7.09-0.2%$6.92$5.65▼$9.92$245.23M0.91153,487 shs2,463 shsHRTXHeron Therapeutics$0.95-0.2%$0.97$0.74▼$2.30$179.77M1.71.95 million shs876,699 shsIBIOiBio$1.64-1.5%$2.10$0.56▼$3.82$59.09M1.231.49 million shs131,934 shsVYGRVoyager Therapeutics$4.17+1.1%$4.03$2.64▼$5.55$251.05M1.26649,863 shs129,876 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFENCAdherex Technologies+2.45%+8.56%+22.20%-8.86%+18.93%HRTXHeron Therapeutics-21.05%-24.78%+11.99%-24.78%-54.73%IBIOiBio-2.92%+4.40%-23.15%-26.87%+165,999,900.00%VYGRVoyager Therapeutics+1.73%+9.57%+10.16%+11.35%+27.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFENCAdherex Technologies 2.57Moderate Buy$14.80108.77% UpsideHRTXHeron Therapeutics 2.20Hold$4.50372.19% UpsideIBIOiBio 3.17Buy$4.75190.52% UpsideVYGRVoyager Therapeutics 2.75Moderate Buy$16.50296.16% UpsideCurrent Analyst Ratings BreakdownLatest IBIO, VYGR, FENC, and HRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/11/2026HRTXHeron Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/21/2026FENCAdherex Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026HRTXHeron Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/16/2026FENCAdherex Technologies WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$13.004/15/2026VYGRVoyager Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026IBIOiBio Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.003/27/2026IBIOiBio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026HRTXHeron Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold3/25/2026FENCAdherex Technologies Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell3/25/2026VYGRVoyager Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFENCAdherex Technologies$44.64M5.49N/AN/A$1.04 per share6.82HRTXHeron Therapeutics$154.90M1.16N/AN/A$0.07 per share13.61IBIOiBio$400K147.72N/AN/A$0.90 per share1.82VYGRVoyager Therapeutics$40.37M6.23N/AN/A$3.53 per share1.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFENCAdherex Technologies-$9.74M-$0.34N/A8.34N/A-22.62%-183.18%-15.31%5/14/2026 (Estimated)HRTXHeron Therapeutics-$20.19M-$0.13N/A7.94N/A-13.04%N/A-4.62%N/AIBIOiBio-$18.38M-$1.00N/AN/AN/AN/A-71.26%-57.92%5/15/2026 (Estimated)VYGRVoyager Therapeutics-$119.72M-$1.97N/AN/AN/A-319.61%-53.03%-40.56%N/ALatest IBIO, VYGR, FENC, and HRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q3 2026IBIOiBio-$0.06N/AN/AN/A$0.02 millionN/A5/14/2026Q1 2026FENCAdherex Technologies-$0.02N/AN/AN/A$13.90 millionN/A5/11/2026Q1 2026HRTXHeron Therapeutics-$0.03-$0.04-$0.01-$0.04$36.72 million$34.71 million5/7/2026Q1 2026VYGRVoyager Therapeutics-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 million3/24/2026Q4 2025FENCAdherex Technologies$0.0423-$0.17-$0.2123-$0.17$14.75 million$13.78 million3/24/2026Q4 2025FENCAdherex Technologies$0.03-$0.17-$0.20-$0.17$14.73 million$13.78 million3/9/2026Q4 2025VYGRVoyager Therapeutics-$0.54-$0.46+$0.08-$0.46$10.49 million$13.46 million2/26/2026Q4 2025HRTXHeron Therapeutics-$0.03-$0.02+$0.01-$0.02$39.53 million$40.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFENCAdherex TechnologiesN/AN/AN/AN/AN/AHRTXHeron TherapeuticsN/AN/AN/AN/AN/AIBIOiBioN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFENCAdherex TechnologiesN/A6.376.23HRTXHeron Therapeutics10.592.481.51IBIOiBioN/A9.049.04VYGRVoyager TherapeuticsN/A7.647.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFENCAdherex Technologies55.51%HRTXHeron Therapeutics80.01%IBIOiBio7.90%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipFENCAdherex Technologies10.73%HRTXHeron Therapeutics5.86%IBIOiBio2.75%VYGRVoyager Therapeutics12.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFENCAdherex Technologies1034.54 million30.84 millionOptionableHRTXHeron Therapeutics300188.64 million177.59 millionOptionableIBIOiBio10036.14 million35.15 millionN/AVYGRVoyager Therapeutics10060.42 million52.75 millionOptionableIBIO, VYGR, FENC, and HRTX HeadlinesRecent News About These CompaniesVoyager Therapeutics (NASDAQ:VYGR) Rating Lowered to Sell at Wall Street ZenMay 9 at 1:34 AM | marketbeat.comVoyager Therapeutics (NASDAQ:VYGR) Announces Quarterly Earnings ResultsMay 7, 2026 | marketbeat.comVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comVoyager Reports First Quarter 2026 Financial and Operating ResultsMay 7, 2026 | globenewswire.comVoyager Therapeutics (VYGR) to Release Quarterly Earnings on MondayMay 4, 2026 | marketbeat.comH.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)May 1, 2026 | theglobeandmail.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s DiseaseApril 28, 2026 | markets.businessinsider.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's DiseaseApril 27, 2026 | globenewswire.comVoyager Therapeutics (NASDAQ:VYGR) Share Price Crosses Above Fifty Day Moving Average - Here's WhyApril 22, 2026 | marketbeat.comVoyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026April 13, 2026 | seekingalpha.comAlfred Sandrock Sells 11,511 Shares of Voyager Therapeutics (NASDAQ:VYGR) StockApril 4, 2026 | insidertrades.comVoyager Therapeutics (VYGR) price target increased by 12.22% to 17.17March 27, 2026 | msn.comVoyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum TranscriptMarch 23, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI), Voyager Therapeutics (VYGR) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)March 19, 2026 | theglobeandmail.comGuggenheim Remains a Buy on Voyager Therapeutics (VYGR)March 13, 2026 | theglobeandmail.comDoes Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?March 12, 2026 | finance.yahoo.comVoyager Therapeutics: Q4 Earnings SnapshotMarch 10, 2026 | finance.yahoo.comVoyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesMarch 9, 2026 | zacks.comVoyager Reports Fourth Quarter and Full Year 2025 Financial and Operating ResultsMarch 9, 2026 | globenewswire.comVoyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference TranscriptMarch 3, 2026 | seekingalpha.comTodd Alfred Carter Sells 4,174 Shares of Voyager Therapeutics (NASDAQ:VYGR) StockFebruary 27, 2026 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIBIO, VYGR, FENC, and HRTX Company DescriptionsAdherex Technologies NASDAQ:FENC$7.09 -0.01 (-0.15%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more.Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Heron Therapeutics NASDAQ:HRTX$0.95 0.00 (-0.24%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.iBio NASDAQ:IBIO$1.64 -0.03 (-1.51%) As of 11:03 AM Eastern This is a fair market value price provided by Massive. Learn more.iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.Voyager Therapeutics NASDAQ:VYGR$4.16 +0.05 (+1.09%) As of 11:04 AM Eastern This is a fair market value price provided by Massive. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
